| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Jardon, N Bonaventur. Different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry. Vision research. vol 35. issue 19. 1995-12-12. PMID:7483308. |
the monocular okn n-t component still appears after administration of piribedil even if this injection is preceded by administration of haloperidol which blocks the dopaminergic d2 receptors. |
1995-12-12 |
2023-08-12 |
Not clear |
| Y Fischer, J Thomas, J Kamp, E Jüngling, H Rose, Carpéné, H Kammermeie. 5-hydroxytryptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction. The Biochemical journal. vol 311 ( Pt 2). 1995-11-28. PMID:7487898. |
the effect of 5-ht was not affected by (i) the 5-ht receptor antagonists methysergide (1 microm), ketanserin (1 microm), cyproheptadine (1 microm), mdl 72222 (1 microm) or ics 205-930 (3 microm), nor by (ii) the adrenergic receptor antagonists prazosin (1 microm), yohimbine (1 microm) or propranolol (5 microm), nor by (iii) the dopaminergic antagonists sch 23390 (1 microm) or haloperidol (1 microm). |
1995-11-28 |
2023-08-12 |
rat |
| M Volonté, A Ceci, F Borsin. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. The Journal of pharmacology and experimental therapeutics. vol 275. issue 1. 1995-11-21. PMID:7562571. |
the in vivo brain microdialysis technique has been used to study the ability of itasetron, [dau 6215, (3-alpha-tropanyl)1h-benzimidazolone-3-carboxamide hydrochloride], a novel 5-hydroxytryptamine3 (5-ht3)-receptor antagonist, to antagonize the effect of the sigma-agonist (+)-n-allylnormetazocine (skf 10,047) in inducing the release of dopamine from mesolimbic and nigrostriatal dopaminergic neurons, in comparison with haloperidol and clozapine. |
1995-11-21 |
2023-08-12 |
rat |
| J M Cook-Mills, R L Cohen, R L Perlman, D A Chamber. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology. vol 85. issue 4. 1995-11-20. PMID:7558147. |
the inhibition of lymphocyte activation by catecholamines could not be reversed by antagonists to beta-adrenergic receptors (propranolol), alpha-adrenergic receptors (phentolamine), or dopaminergic receptors (haloperidol). |
1995-11-20 |
2023-08-12 |
mouse |
| U Freo, P Pietrini, G Pizzolato, M Furey-Kurkjian, A Merico, S Ruggero, M Dam, L Battisti. Dose-dependent effects of buspirone on behavior and cerebral glucose metabolism in rats. Brain research. vol 677. issue 2. 1995-11-14. PMID:7552245. |
instead these changes resemble the rcmrglc effects of dopaminergic d2 antagonists like haloperidol and are consistent with some pharmacological and binding properties of buspirone. |
1995-11-14 |
2023-08-12 |
rat |
| A Vamvakidè. [Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy]. Bollettino chimico farmaceutico. vol 134. issue 5. 1995-10-25. PMID:7546535. |
on the other hand at 150 mg/kg (ip), a dose which potentiated the haloperidol catalepsy, pg stimulated the dopaminergic function in the striatum. |
1995-10-25 |
2023-08-12 |
mouse |
| J Perez, Z Perez, J Angel, J Charris, M Torres, A Israe. Synthesis of (+/-)-1-amino-6,7,8,8a-tetrahydro acenaphthene with possible central dopaminergic activity. Bollettino chimico farmaceutico. vol 134. issue 6. 1995-10-25. PMID:7546539. |
the renal actions of 14 were blocked by haloperidol pretreatment, suggesting that 14 acts centrally through a dopaminergic mechanism. |
1995-10-25 |
2023-08-12 |
rat |
| A Mele, C Castellano, V Cestari, A Oliveri. Interaction between the NMDA competitive antagonist CPP and the dopaminergic system in one-trial inhibitory avoidance in C57BL/6 mice. Neurobiology of learning and memory. vol 63. issue 2. 1995-10-10. PMID:7663887. |
furthermore, subchronic blockade of dopamine receptor through a 10-day daily treatment with 4 mg/kg of haloperidol induced an adaptation of both the dopaminergic and the glutamatergic system. |
1995-10-10 |
2023-08-12 |
mouse |
| M Smiałowsk. An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neurons. Neuroscience. vol 66. issue 3. 1995-09-21. PMID:7644023. |
it was found that monoamine depletion by reserpine, the blockade of dopaminergic receptors by haloperidol or the specific d1 receptor blockade by sch23390 caused a significant increase in the neuropeptide y immunoreactivity in the cortex studied, after 24 h, evaluated as the density of immunoreactive neurons. |
1995-09-21 |
2023-08-12 |
rat |
| T P Shevchenko, B A Tolpyshev, A A Dutov, L I Povaliaev. [Analysis of functional and biochemical changes in feline cerebral hemispheres after subchronic haloperidol administration]. Patologicheskaia fiziologiia i eksperimental'naia terapiia. issue 1. 1995-08-15. PMID:7609996. |
feline experiments have revealed that subchronic haloperidol causes asymmetric changes in the mesencephalic levels of dopamine and serotonin and impairs intrahemispheric balance between the dopaminergic and serotoninergic systems. |
1995-08-15 |
2023-08-12 |
Not clear |
| Y Ohno, K Ishida, T Ishibashi, K Ikeda, T Kato, M Nakamur. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. General pharmacology. vol 26. issue 3. 1995-07-27. PMID:7789721. |
changes in behavioral dopaminergic and serotonergic sensitivities were studied in rats after withdrawal of the chronic treatments with sm-9018 (0.1 mg/kg/day), a potential atypical neuroleptic, and with haloperidol (0.3 mg/kg/day) using continuous infusion pumps. |
1995-07-27 |
2023-08-12 |
rat |
| Y Ohno, K Ishida, T Ishibashi, K Ikeda, T Kato, M Nakamur. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. General pharmacology. vol 26. issue 3. 1995-07-27. PMID:7789721. |
these findings suggest that sm-9018 is weaker than haloperidol in inducing the behavioral dopaminergic hypersensitivity after its chronic treatment and has a lower propensity to cause tardive dyskinesia. |
1995-07-27 |
2023-08-12 |
rat |
| M A Vital, R Frussa-Filho, J Palermo-Net. Effects of monosialoganglioside on dopaminergic supersensitivity. Life sciences. vol 56. issue 26. 1995-07-25. PMID:7791517. |
the effects of monosialoganglioside (gml) treatment on dopaminergic supersensitivity induced by long-term haloperidol administration were studied; both general activity of rats observed in an open-field and apomorphine-induced stereotyped behavior were used as experimental parameters. |
1995-07-25 |
2023-08-12 |
rat |
| S Mukhopadhyay, M K Podda. Caffeine-induced locomotor activity: possible involvement of GABAergic-dopaminergic-adenosinergic interaction. Neurochemical research. vol 20. issue 1. 1995-06-07. PMID:7739757. |
or dopaminergic antagonist, haloperidol (0.25-1 mg/kg, i.p.) |
1995-06-07 |
2023-08-12 |
rat |
| D N Velázquez Martínez, M Valencia Flores, M López Cabrera, J E Villarrea. Effects of indorenate on food intake: a comparison with fenfluramine and amphetamine. Psychopharmacology. vol 117. issue 1. 1995-05-25. PMID:7724707. |
haloperidol, a dopaminergic antagonist, was ineffective in preventing the effect of indorenate although it prevented the anorectic effect of amphetamine. |
1995-05-25 |
2023-08-12 |
Not clear |
| N A Keks, D L Copolov, D P McKenzie, J Kulkarni, C Hill, J D Hope, B S Sing. Basal and haloperidol-stimulated prolactin and symptoms of nonaffective and affective psychoses in neuroleptic-free men. Biological psychiatry. vol 37. issue 4. 1995-05-18. PMID:7711159. |
the prolactin (prl) response to 0.5 mg of intravenous haloperidol (hpl) iv may be a measure of tuberoinfundibular dopaminergic activity. |
1995-05-18 |
2023-08-12 |
Not clear |
| M A Cheido, G V Idov. Participation of opiate delta-receptors in immunomodulation. Neuroscience and behavioral physiology. vol 24. issue 6. 1995-05-16. PMID:7715767. |
the increase in the immune response obtained with the administration of ici 174,864 is associated with the dopaminergic system, since it is prevented by haloperidol. |
1995-05-16 |
2023-08-12 |
mouse |
| G Mereu, V Lilliu, P Vargiu, A L Muntoni, M Diana, G L Gess. Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. European journal of pharmacology. vol 264. issue 3. 1995-04-28. PMID:7698187. |
however, when neuronal sampling was performed in unanesthetized rats, chronic administration of haloperidol (daily for 21-28 days) failed to reduce the incidence of active dopaminergic neurons. |
1995-04-28 |
2023-08-12 |
rat |
| L W Fitzgerald, A Y Deutch, G Gasic, S F Heinemann, E J Nestle. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 15. issue 3 Pt 2. 1995-04-17. PMID:7891180. |
these findings indicate that the dopaminergic antagonist properties of haloperidol are likely most responsible for its regulation of this subunit. |
1995-04-17 |
2023-08-12 |
Not clear |
| L L Demchyshyn, K S Sugamori, F J Lee, S A Hamadanizadeh, H B Nizni. The dopamine D1D receptor. Cloning and characterization of three pharmacologically distinct D1-like receptors from Gallus domesticus. The Journal of biological chemistry. vol 270. issue 8. 1995-03-31. PMID:7876148. |
in contrast, the d1d receptor bound dopaminergic agents, such as skf-38393, apomorphine, pergolide, and lisuride, with affinities 10-fold higher than other cloned mammalian or vertebrate d1a/d1b receptor subtypes, while both clozapine and haloperidol displayed considerably lower affinity for the d1d receptor. |
1995-03-31 |
2023-08-12 |
Not clear |